Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 + PD-1/VEGF Bispecific Antibody vs Chemotherapy + PD-1/VEGF Bispecific Antibody in 1L Squamous NSCLC
NCT07739199Phase 3Not yet recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in squamous cell carcinoma of the lung (SCCL), sponsored by Biokin Pharmaceutical. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT07739199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07739199.